In a recent interview with Medsider, Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), outlined the company's strategy to expand access to robotic surgery through affordable technology, physician training, and remote surgical capabilities. The discussion emphasized that for investors evaluating emerging medical technology companies, understanding competitive advantages is as crucial as financial performance.
Affordability and accessibility remain core priorities as SS Innovations expands its surgical robotics platform globally. The company's SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery. Artificial intelligence, automation, and new robotic platforms are central to the long-term product roadmap.
Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely. The company has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries. SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets.
Rather than solely competing with existing robotic surgery platforms, Dr. Srivastava described SS Innovations’ objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery due to equipment costs and operating expenses. The company's strategy aims to democratize robotic surgery by making it more affordable and accessible worldwide.
For more details, the full interview and terms of use are available on the InvestorBrandNetwork website: http://IBN.fm/Disclaimer. Forward-looking statements in this article involve risks and uncertainties as described in the company's SEC filings.
